Personalizing oral delivery of nanoformed piroxicam by semi-solid extrusion 3D printing.

Autor: Mathiyalagan R; Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Tykistökatu 6A, 20520 Turku, Finland., Sjöholm E; Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Tykistökatu 6A, 20520 Turku, Finland., Manandhar S; Nanoform Finland Ltd, Viikinkaari 4, 00790 Helsinki, Finland., Lakio S; Nanoform Finland Ltd, Viikinkaari 4, 00790 Helsinki, Finland., Rosenholm JM; Nanoform Finland Ltd, Viikinkaari 4, 00790 Helsinki, Finland., Kaasalainen M; Nanoform Finland Ltd, Viikinkaari 4, 00790 Helsinki, Finland. Electronic address: martti.kaasalainen@nanoform.com., Wang X; Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Tykistökatu 6A, 20520 Turku, Finland. Electronic address: xiaoju.wang@abo.fi., Sandler N; Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Tykistökatu 6A, 20520 Turku, Finland; Nanoform Finland Ltd, Viikinkaari 4, 00790 Helsinki, Finland.
Jazyk: angličtina
Zdroj: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [Eur J Pharm Sci] 2023 Sep 01; Vol. 188, pp. 106497. Date of Electronic Publication: 2023 Jun 16.
DOI: 10.1016/j.ejps.2023.106497
Abstrakt: Semi-solid extrusion (SSE) 3D printing enables flexible designs and dose sizes to be printed on demand and is a suitable tool for fabricating personalized dosage forms. Controlled Expansion of Supercritical Solution (CESS®) is a particle size reduction technology, and it produces particles of a pure active pharmaceutical ingredient (API) in a dry state, suspendable in the printing ink. In the current study, as a model API of poorly water-soluble drug, nanoformed piroxicam (nanoPRX) prepared by CESS® was accommodated in hydroxypropyl methylcellulose- or hydroxypropyl cellulose-based ink formulations to warrant the printability in SSE 3D printing. Importantly, care must be taken when developing nanoPRX formulations to avoid changes in their polymorphic form or particle size. Printing inks suitable for SSE 3D printing that successfully stabilized the nanoPRX were developed. The inks were printed into films with escalating doses with exceptional accuracy. The original polymorphic form of nanoPRX in the prepared dosage forms was not affected by the manufacturing process. In addition, the conducted stability study showed that the nanoPRX in the prepared dosage form remained stable for at least three months from printing. Overall, the study rationalizes that with nanoparticle-based printing inks, superior dose control for the production of personalized dosage forms of poorly water-soluble drugs at the point-of-care can be achieved.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: